A Study of NX-1607 in Adults With Advanced Malignancies
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to
evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced
malignancies.